Targeted cancer immunotherapy: Mimicking physiological trans-presentation of IL-15
D. Müller. OncoImmunology1 (7):
Under physiological conditions, the trans-presentation of interleukin-15 (IL-15) by the IL-15 receptor alpha on the cell surface allows to confine and tune the IL-15-mediated immune responses. Therefore, targeting strategies that mimic this situation at the tumor sites appear especially promising for anticancer immunotherapy.